The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I've always wondered if the MMs have access to the stop-loss information on the platforms of online brokers. i.e. where brokers make markets and offer execution only services. Does anyone know if this is legal? I've avoided using stop-losses for small shares since getting taken out by a tree-shake on tristel TSTL at about 80p years ago. Gutted!
I disagree about StoneChecker being a white elephant. I did some research and calculations calculations about 3 years ago which suggested based on wide adoption of the software globally it alone justified a market cap of £150M. This was my premise:
The cost of a single lithotripsy treatment is around £750 in India or the
Philipines. If we adopt this as an average global cost, assume a potential population with
access to treatment of 3 billion people, and assume that StoneChecker is licensed for use on
a single patient by StoneChecker Software Ltd for 0.1% of the cost of a single lithotripsy
treatment, this indicates an annual revenue stream of £18M. Software companies have
relatively fixed costs, so the overwhelming majority of this revenue should become net
income. If we assume a price-earnings ratio of 10, this implies a market cap around £150M
once StoneChecker is widely adopted.
Obviously with the additional potential products now, I am quite optimistic about this share even from the baseline of the almost 200% rise yesterday. I have more than 3-bagged. I am not selling!
completely agree - having had a really awful time myself with uncontrolled bleeding after the big canula for contrast agent was removed following a scan - I think being able to acquire the same information without contrast agent will be enthusiastically embraced!
welcome Dufflebagboy! I don't post a lot myself, mostly lurk.There are some useful gems amidst a lot of hope/speculation/ramping/deramping on these boards. There was a great nugget posted here about Cardiff council's support of IQE's expansion, which was public-domain but off the radar of most investors/traders. Personally I'm a long-term holder - I think if you find a company with good growth prospects that's the safest / easiest / most rewarding approach. I've held IQE for years and my average buy-in price was under 20p until I topped up recently around 100p. Of course topping up has delayed my chances of 10-bagging overall, but a profit is a profit! GLAH
yes it was nice to read Simon Thompson more or less agreeing with what Noirgold posted here earlier! My only regret on this is that I didn't buy more of this that I did when it was 77p in November 2016... Simon Thompson had already tipped it at a higher price, and I was worried that the market knew something I didn't.
Thanks NG. Yes I see. Cash burn implies turnover. Then you extrapolated the last published run-rate to estimate likely run-rate for each month Jan-June 2017, producing a total consistent with the known cash burn. Did you assume linear growth Dec16 - June17? (Obviously I could make a graph and find out, but why reinvent your fine wheel?)
Good thread topic Slowburner. Thanks for those figs Noirgold. Are they lifted from BGO reports? At current market of £126M, and assuming costs remain £5M p.a. Noirgold's prediction implies net earnings of approx £7M for 2018 (assuming no growth in revenue or EUS after dec 2017), or a PE of 18 at the current SP. This seems extraordinarily cheap for a company with BGO's growth prospects!